Coherus Oncology (CHRS) stock

Worth $99MShares as of Oct 31

$0.64

-21.61%

As of Tuesday's close · Live for Pro members at the open

Not scored

Breakaway doesn't score CHRS. It is priced too low for a fair Quality Score.

Healthcare · Biotech

Next1H 2027“…casdozokitug/toripalimab/bevacizumab in 1L uHCC is complete and the first data readout is expected in 1H 2027…”Trial data · SEC filing · Nov 9

Cash$83.6M, about 1 quarter at the last year's spendingOn Sep 30

Follow CHRS's trial news. Pro members can get an alert when Coherus Oncology files news, and see its trials, share raises, and its CEO's filings.

Get an alert when CHRS files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. 3,168 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live.

Cash$83.6M, about 1 quarter at the last year's spendingOn Sep 30

What's next for CHRS, and how long its cash lasts

Next step the company has named

1H 2027“Enrollment in the randomized Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L uHCC is complete and the first data readout is expected in 1H 2027.”Trial data · SEC filing · Nov 9

What it means: the first look at a trial’s main results, as the company reports them.

Lead program: Casdozokitug · Hepatocellular Carcinoma · Phase 2
Its trial: Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular CarcinomaPhase 2 · Active · 72 people · main data estimated Sep 2027 · NCT06679985

4 more trials, 54 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 1 quarter

$83.6M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Nov 13, 2025)
At-the-market share sales program (424B5, filed Aug 28, 2026)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From Form 4: open-market buys and sales only.

Get an alert when Dennis Lanfear buys or sells

For Pro members: every trade, and Dennis Lanfear’s 14 filings and quotes.

Get an alert when CHRS files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

CHRS's latest filings

Quarterly report10-Q, filed Nov 9
Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan8-K, filed Nov 9
Prospectus for a sale of securities424B5, filed Aug 28

26 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why CHRS isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares or $10M a day. CHRS trades at $0.64. A stock that clears every mark is scored from the next weekly rebuild.

Straight AnswersStraight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.